West Pharmaceutical Services (WST) Projected to Post Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is projected to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect West Pharmaceutical Services to post earnings of $1.83 per share and revenue of $795.6980 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $237.09 on Thursday. The firm has a market cap of $17.06 billion, a PE ratio of 35.12, a price-to-earnings-growth ratio of 3.18 and a beta of 1.18. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $335.64. The business’s fifty day simple moving average is $265.64 and its 200-day simple moving average is $261.58.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th were given a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 13.04%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in West Pharmaceutical Services in the second quarter valued at approximately $47,000. State of Wyoming acquired a new stake in West Pharmaceutical Services during the second quarter worth approximately $49,000. Darwin Wealth Management LLC purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $75,000. Finally, Parallel Advisors LLC grew its position in shares of West Pharmaceutical Services by 21.0% in the 3rd quarter. Parallel Advisors LLC now owns 398 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 69 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on WST. Wall Street Zen upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Evercore ISI dropped their target price on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a report on Tuesday. TD Cowen initiated coverage on West Pharmaceutical Services in a research report on Wednesday, October 29th. They issued a “buy” rating on the stock. Barclays raised their price target on West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $328.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.